rucaparib + carboplatin

Rucaparib + carboplatin is a **combination therapy** under investigation for advanced solid tumors, especially in patients with breast, ovarian, and peritoneal cancers. **Rucaparib** is a small-molecule inhibitor of poly(ADP-ribose) polymerase (PARP), which disrupts the repair of single-strand DNA breaks and leads to cell death in homologous recombination-deficient cells (such as those with *BRCA1* or *BRCA2* mutations). **Carboplatin** is a platinum-based chemotherapeutic agent that causes DNA damage, primarily DNA crosslinking, and induces apoptosis in rapidly dividing cells. The combination leverages synergistic cytotoxicity: carboplatin induces DNA damage, while rucaparib inhibits DNA repair, resulting in increased cell death. The recommended phase II dose for the combination is oral rucaparib 240 mg once daily (days 1–14) plus carboplatin area under the curve (AUC) 5 administered on day 1 of a 21-day cycle. The combination results in more frequent hematological toxicities, particularly neutropenia and thrombocytopenia. The therapy is being studied for its efficacy in BRCA-mutant and BRCA-wild-type tumors and shows radiologic antitumor activity in advanced settings[1][2].

Brand names

Rubraca (for rucaparib)Paraplatin (for carboplatin)

Other names

rucaparib + carboplatin